T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schöfl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A.
Potorac I, et al. Among authors: devuyst f.
Endocr Relat Cancer. 2016 Nov;23(11):871-881. doi: 10.1530/ERC-16-0356. Epub 2016 Sep 20.
Endocr Relat Cancer. 2016.
PMID: 27649724
Free article.
Clinical Trial.